The utility of natural products for identifying anticancer agents has been highly pursued in the last decades and over 100 drug molecules in clinic are natural products or natural product-derived compounds. Natural products are believed to be able to cover unexplored chemical space that is normally not occupied by commercially available molecule libraries. However, the low abundance and synthetic intractability of natural products have limited their applications in drug discovery. Recently, the identification of biologically relevant fragments derived from biologically validated natural products has been recognized as a powerful strategy in searching new biological probes and drugs. The spirocyclic oxindoles, as privileged structural scaffolds, have shown their potential in designing new drugs. Several anticancer drug candidates such as SAR405838, RO8994, CFI-400945 and their bioisosteres are undergoing clinical trials or preclinical studies. To highlight the significant progress, we focus on illustrating the discovery of SAR405838, RO8994, CFI-400945 and their bioisosteres for cancer therapy using substructure-based strategies and discussing modes of action, binding models and preclinical data.
INTRODUCTION
Natural products have played a pivotal role in new drug discovery, over 100 natural products or natural product-derived compounds are currently undergoing clinical evaluation at different phases [1] [2] [3] . Natural products continue to be a rich source of novel structures for identifying anticancer agents, about 48.6% of small molecule anticancer drugs reported from around 1981 to 2010 are natural products or compounds directly derived from them [4] . And the influence of natural products on developing other types of new drugs especially the antibiotics is also quite marked. Natural products are structurally more diversified, complex, and rich in stereogenic centers that make them privileged in covering biologically relevant chemical space not explored by available screening collections [5, 6] . However, the low abundance and synthetic intractability of natural products have limited their applications in drug discovery. Therefore, the identification of natural product-derived fragments based on the analysis of biologically validated natural products following the established criteria for fragment likeness have recently drawn increasing attention in searching new biological probes and drugs [7] . For example, the uracil, a fragment present in numerous natural products, was successfully used as a starting point in the Riedl group to design potent and selective matrix metalloproteinase 13 (MMP-13) inhibitors, one of which inhibited MMP-13 with a K i value of 11 nM ( Fig. 1) [8] . Dimerization of the structurally simplified inactive 2-pyridone fragment of (-)-Huperzine A produced a drug, which was twice more potent than natural (-)-Huperzine A [9] . Based on the binding models of the spiro-pyrrolidinyl oxindoles in the MDM2 active site, Wang et al. designed potent MDM2 inhibitor SAR405838 for cancer therapy utilizing the substructure-based de novo drug design strategy [10] . The fragments derived from biologically validated natural products are normally much easier to *Address correspondence to these authors at the School of Pharmaceutical Sciences and New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, P. R. China; Tel/Fax: 0086-371-677817390; E-mails: liuhm@zzu.edu.cn and zzuyubin@hotmail.com be synthesized than natural products, while these fragments retain the structural features of natural products such as the diversity, complexity and novelty. Such fragments equipped with functional groups for linking would serve as templates for constructing natural product-like compound collections.
Of particular interest are spiro scaffolds which are prevalent in natural products and pharmaceutically active agents [11] . It is well believed that spirocyclic compounds have a reduced conformational entropy upon binding to a protein target, as well as conformational restriction [12] . Additionally, the non-flat and three-dimensional structural features of spiro scaffolds could help achieve specific binding to their respective targets [13, 14] . All these features make spiro scaffolds promising in drug discovery. Among them, the spirocyclic oxindoles have drawn extensive attention because of their prevalence in numerous natural products (e.g. Spirotryprostatin A and B) and biologically active molecules (e.g. SAR405838, CFI-400945 and KAE609, etc) [15] [16] [17] . The structural characteristics of these compounds lie in that the heterocyclic motif and the oxindole core are connected through a quaternary carbon at the 3-position of oxindole core. Recently, spirooxindoles have been highly pursued as substructures for designing new anticancer drugs [16, 18, 19] , generating SAR405838 [12] , RO8994 [20, 21] , CFI-400945 [22, 23] and their bioisosteres, which are undergoing preclinical or clinical assessment. The spirooxindole scaffolds with antitumor activity are summarized in Fig. 2 , substituents around the scaffolds are omitted and the number 'n' denotes the ring size of heterocyclic motif (Highlighted in bold in Fig. 2 ) fused at the 3-position of oxindole core.
Among these scaffolds, spiro cyclopropyl and pyrrolidinyl oxindoles and their bioisosteres have shown their promise in new drug development. To highlight the significant progress in this field, in this review, we illustrate the discovery of CFI-400945, SAR405838 and RO8994 (Fig. 3) with a particular emphasis on strategies employed for optimizations, modes of action and their preclinical data. This review is organized based on the molecular targets of these drug leads.
DISCOVERY OF SPIROOXINDOLE-BASED ANTICANCER AGENTS

PLK4 Inhibitors
In mammalian cells, five members of the polo-like kinase family (PLKs 1-5) belonging to highly conserved serine/threonine kinases have been reported [24] since it was first cloned from Drosophila melanogaster in 1988 [25] . PLKs 1-4 are structurally similar in the N-terminal serine/threonine kinase catalytic domains, the C-terminal regulatory domain contains one or two polo-boxes (for PLK4 and PLKs 1-3, respectively) [26] [27] [28] . Differently, PLK5 is a protein lacking the kinase domain [29] (Fig. 4) . PLKs 1-3 and PLK4 function differently as phosphopeptide binding domains and a homodimerization domain, respectively because of the structural difference in C-terminal domains [30, 31] . Of the PLKs family, PLK1 has been extensively studied with several inhibitors undergoing clinical/preclinical development [28, [32] [33] [34] . However, much less is known about the structurally divergent PLK4, which has been reported to be able to control centriole duplication [35] , maintain chromosomal stability [36] and affect cancer cell invasion [37] . Besides, the depletion of PLK4 in human breast cancers can prevent centriole duplication [38, 39] . More importantly, PLK4 overexpression has been observed in about 80% of human tumor cells. Therefore, PLK4 would be a new and promising therapeutical target for designing small-molecule inhibitors for anticancer treatment. Currently, only two classes of potent PLK4 inhibitors, namely CFI-400945 [23, [40] [41] [42] [43] and LCR-263 [44] have been disclosed with K i values of 0.28 and 0.16 nM, respectively. LCR-263 inhibits PLK4 reversibly and potently and is highly selective to PLK4 over Aurora A and B (2100-and 9500-fold, respectively). CFI-400945 is the first potent PLK4 inhibitor (K i = 0.26 nM) reported by Pauls and co-workers in 2015 [45] .
Orally active CFI-400945 is undergoing phase 1 clinical trials approved by Health Canada and the FDA for studying safety and efficacy in patients with advanced cancer (ClinicalTrials.gov Identifier: NCT01954316). Preclinical studies showed that CFI-400945 inhibited growth of a panel of cancer cells of different origins at nanomolar levels and was well tolerated in phosphatase and tensin homolog (PTEN)-deficient breast cancer xenograft models [46] [47] [48] . Mechanistically, CFI-400945 controlled the centriole number precisely through balancing phosphorylation of downstream substrates and autophosphorylation, finally blocking Polo-box domain Polo-box domain PLK4 expression [49] [50] [51] . The preclinical data of CFI-400945 are presented in Table 1 . From this and 3A4 isoforms at micromolar levels but no inhibition toward 1A2 and 2D6 isoforms was observed. Human microsomal T 1/2 was over 60 min, significantly longer than that of other species. Upon oral dosing, high plasma levels in mouse were observed (C max = 2.2 µg/mL, AUC = 9.8 µ g·h/mL), significantly higher than those represented by other analogs with basic piperazinyl and (alkylpiperidin-4-yl)oxy moieties (data not shown here) [45] . The authors proposed that the large increase in exposure of CFI-400945 may be attributed to the attenuation of the basicity of nitrogen by the oxygen atom in the morpholine, thus achieving a balance between enhanced solubility at low pH and good permeability at physiological pH.
To show the role of each structural motif in the binding between CFI-400945 and the PLK4 active site (PDB code: 4JXF), the representative binding model generated by GlideXP docking is depicted in Fig. 5 . Evidently, the interactions between CFI-400945 and PLK4 are mainly mediated by four hydrogen bonds and the compact hydrophobic contact at the aromatic rings. The morpholine group exposed to the solvent region may benefit the hydrophobic contact. The methoxy group attached to the oxindole core is placed at the cleft formed by the protein backbone and the Leu143 and Glu96 side chains.
The program of identifying potent PLK4 inhibitors was initiated in 2013 in the Pauls's group (Fig. 6) [40] .
After screening a kinase library (about 8,000 compounds) against PLK4 through the indirect Elisa assay, they found that 4-hydroxybenzylideneindolin-2-one (compound 1) can inhibit PLK4 at micromolar levels (IC 50 = 32 µM). Subsequent modification by the bioisosteric replacement strategy gave compound 2 which showed significantly enhanced inhibition against PLK4 (IC 50 = 0.29 µM). Axitinib as a tyrosine kinase inhibitor has been reported to be able to inhibit growth of breast cancer significantly in xenograft models [30] . Therefore, hybridization of indolinone 2 and Axitinib generated indolinone 3 with an IC 50 value of 13 nM. Further modifications focusing on variations of substituents on the indolinone ring, the position of the pyridinyl nitrogen and the incorporation of water-solubilizing substituents on the phenyl ring distal from the indazole core yielded indolinone 4, which displayed higher potency (IC 50 = 4 nM), excellent selectivity toward PLK4 over other PLK family members, decreased CYP450 inhibition and improved PK profiles [40, 41] . Further cyclopropanation of compound 4, coupled with variations of terminal hydrophilic group gave conformationally restricted racemic indolinone 5, which was endowed with improved ADME properties and oral exposure [41] . The modeling studies revealed that the (1R,2S)-enantiomer had preferential binding affinity to PLK4. Interestingly, (1R,2S)-compound 6 showed comparable PLK4 inhibition (IC 50 = 1.4 nM) with high clearance rates in rat (CL = 3.2 L · h/kg). In order to improve the PK properties, Modifications on the indolinone core and solubilizing groups attached to the phenyl ring yielded the potent, orally active antitumor agent CFI-400945 [52] .
MDM2 Inhibitors
In cells, p53 and MDM2 are regulated through an autoregulatory negative feedback loop [53] [54] [55] . Activation of p53 promotes MDM2 transcription, finally leading to an increased expression of MDM2. The overexpressed MDM2 directly binds to the N-terminal domain of p53 and then blocks p53 transcriptional activity [56, 57] . For tumors retaining wild-type p53, their p53 functions are always inhibited by the overexpressed MDM2 oncoprotein [58, 59] . Therefore, p53 has become a promising therapeutic target for anticancer drug discovery through reactivating mutant p53 and restoring p53 function. Historically, protein-protein interactions (PPIs) have long been regarded as undruggable targets because PPIs always involve the large and flat interface [60, 61] . Interestingly, the MDM2-p53 interactions are mediated by a narrow range of amino acid residues [62] . The cocrystal structure of MDM2-p53 complex shows that the 
CFI-400945
GIn160
Lys41
GIu90 Cys92
MDM2-bound p53 peptide adopts the α-helical conformation and interacts with MDM2 primarily through the Phe19, Trp23 and Leu26 residues (Fig. 7) [63] . The structural features of MDM2-p53 complex provides a rationale for designing small molecules that mimic the key residues to block the MDM2-p53 interactions [64] . Currently, small-molecule-induced interruption of MDM2-p53 interactions has been highly pursued, numerous MDM2 inhibitors have been discovered [65] [66] [67] [68] . Among them, spirooxindole-based SAR405838, RO8994 and their bioisosteres are undergoing clinical or preclinical development. SAR405838 (Fig. 3) , as a potent MDM2 inhibitor (K i = 0.88 nM), has entered phase 1 clinical trials for cancer therapy (ClinicalTrials.gov Identifier: NCT01636479 and NCT01985191) [10] . SAR405838 inhibited growth of wild-type p53 containing cancer cells (SJSA-1, RS4;11, LNCaP, and HCT116) at nanomolar levels and displayed over 100-fold selectivity over p53 mutated or depleted cancer cells. Upon oral administration at 100 mg/kg, it achieved complete and durable tumor regression in four types of xenograft models and induced strong apoptosis by upregulating PUMA transcription. As shown in Fig. 7B , SAR405838 mimicked three key residues (Phe19, Trp23, and Leu26) in p53 to occupy the cavities on the surface of MDM2. Also, it captured additional interactions that were not involved in MDM2-p53 interactions. The Cl atom in the oxindole ring provided extensive hydrophobic interaction with MDM2. There was a π-π interaction between His96 and the 2-fluoro-3-chlorophenyl group, along with a hydrogen bond between the imidazole side chain of His96 and the amide carbonyl group of the hydrophilic chain. Besides, SAR405838 can induce refolding of N-terminal domain of MDM2 as well to achieve high binding through Val14 and Thr16 [10] . Drug candidate SAR405838 (K i = 0.88 nM) and its secondgeneration inhibitor MI-1061 (K i = 0.16 nM) were first reported as potent MDM2 inhibitors by the Wang group using the substructurebased de novo drug design strategy (Fig. 8) [69] . As the most 
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A B crucial residue, Trp23 in p53 is inserted into a deep and narrow cavity in MDM2. Interestingly, they found that the oxindole group can closely mimic the Trp23 residue to occupy the hydrophobic pocket in MDM2, while oxindole containing natural Spirotryprostatin A failed to interact with MDM2 effectively [70] . Therefore, the structurally simplified spiro-pyrrolidinyl oxindole core (Highlighted in Red in Fig. 8 ) was then used as a template to design MDM2 inhibitors.
Based on the spiro-pyrrolidinyl oxindole fragment, compound 7 (MI-5) was generated with a moderate binding affinity (K i = 8.46 µM). Docking studies showed that the phenyl and isobutyl groups mimicked the Phe19 and Leu26 in p53, respectively to occupy two hydrophobic pockets, while the oxindole core was inserted into the Trp23 cavity. Variations of substituents on the phenyl ring and amide side chain, coupled with replacement of isopropyl with larger neopentyl group produced compound 9 (MI-63) which showed significantly increased binding affinity (K i = 3.0 nM). Compared to MI-5, MI-63 represented improved potency and metabolic stability. However, the poor PK profiles of MI-63 hampered its in vivo evaluation [71] . Further modifications of the amide side chain and substituents on the phenyl ring and oxindole core of MI-63 yielded compound 10 (MI-219), which represented increased oral bioavailability, albeit with comparable binding affinity with MI-63 (K i = 3.0 nM). However, MI-219 failed to achieve complete tumor regression. Subsequent replacement of diol side chain with conformationally constrained tert-alcohol yielded orally active compound 11 (MI-888, K i = 0.44 nM), which showed improved PK profiles and in vivo antitumor potency and achieved complete and durable tumor regression in two types of xenograft models [72] . The tert-alcohol group in MI-888 was proved to be able to block the CYP450 oxidation. More importantly, MI-888 had all transconfiguration, different from that in MI-219. Compared to MI-219 (K i = 5.0 nM), MI-888 had about 10-fold potency toward MDM2. Replacement of the tert-alcohol group with a trans-4-hydroxycyclohexylamino group yielded SAR405838 (compound 12, K i = 0.88 nM), albeit with slightly decreased binding affinity to MDM2 [10] . SAR405838 is currently undergoing phase 1 assessment for cancer therapy. However, prolonged treatment of SJSA-1 tumor cells with SAR405838 induced different degrees of acquired resistance in vitro and in vivo [73, 74] . Although SAR405838 had the most stable configuration, the isomerization through the ring-opening retro-Mannich reaction in protic solvents still gave an equilibrium mixture of four diastereoisomers. Therefore, Wang et al. designed the second-generation spirooxindoles as MDM2 inhibitors by making pyrrolidine C2 substitution achiral [69] . Further modifications focusing on variations of C2 substituents and hydrophilic amide side chains led to the discovery of MI-1061 (compound 13), which exhibited excellent chemical stability and improved binding affinity to MDM2 (K i = 0.16 nM).
Based on the structures of MI-219 and RG7112 (a drug candidate in phase 1 clinical trials belonging to Nutlin family), the Graves group designed another potent MDM2 inhibitor RG7388 (IC 50 = 6 nM), which has entered phase 1 clinical trials for the treatment of solid and hematological tumors as well (ClinicalTrials.gov Identifier: NCT02407080). Further modifications gave RO8994, RO2468, and RO5353, which showed comparable binding affinities to MDM2 with RG7388 and MI-219 (Fig. 9) .
Initially, they designed compound 14, which bonded to MDM2 with an IC 50 value of 196 nM, significantly more potent than its enantiomer (IC 50 > 10,000 nM) [21] . Replacement of diol side chain with benzoic acid group, coupled with the introduction of fluorine atom to both phenyl rings yielded compound 15, which represented significantly enhanced binding affinity (IC 50 = 22 nM) and improved PK profiles. The introduction of methoxy group to the phenyl ring eventually led to the discovery of RG7388 (compound 16, IC 50 = 6 nM), which was endowed with markedly increased PK profiles and cellular potency/selectivity. Further derivatization of RG7388 by combining the oxindole core and converting the terminal carboxylic acid group to carboxamide group gave RO8994 (compound 17), which showed improved PK properties. Interestingly, bioisosteric replacement of phenyl ring with other heterocycles generated RO2468 (19) and RO5353 (20) , which markedly improved the metabolic stability, PK properties, cellular potency/selectivity, and in vivo efficacy, compared to MI-888 with an aliphatic amide side chain [72, 75] . RG7388 and RO8994 induced p53 stabilization, cell cycle arrest and apoptosis in tumor cells expressing wild type p53 and exhibited impressive in vivo efficacy in human SJSA1 tumor xenograft models [76] . RO8994, RO2468, and RO5353 are undergoing preclinical assessment. In terms of binding to MDM2, this series of compounds showed similar binding model with SAR405838. The 6-chlorooxindole motif occupies the Trp23 pocket with the NH forming a hydrogen bond with the backbone carbonyl of MDM2, while the 2-fluoro-3-chloro phenyl group and the neopentyl group are filled into Leu26 and Phe19 hydrophobic pockets, respectively. In order to exhibit their anticancer potential for clinical development, the preclinical data of RG7388, RO8994, RO2468, and RO5353 are summarized in Table 2 .
CONCLUDING REMARKS AND OUTLOOK
The utility of natural products for identifying anticancer agents has been highly pursued in last decades and over 100 drug molecules in clinic are natural products or natural product-derived derivatives. Natural products are structurally divergent and complex, which allows for covering unexplored chemical space that is not occupied by commercially available molecule libraries. Because of the low abundance and synthetic intractability of natural products, the identification of biologically relevant fragments derived from biologically validated natural products have recently drawn wide attention in searching new biological probes and drugs. These fragments are always much easier to be synthesized than natural products, while retaining the structural complexity of natural products. Such fragments equipped with multifunctional handles would serve as templates for constructing natural productlike compound collections.
Spirocyclic scaffolds have been proved to be able to bind to targets with reduced conformational entropy. Among them, the spirocyclic oxindoles are prevalent in numerous natural products and biologically active molecules and have been frequently used as fragments for designing new drugs in different groups, several anticancer drug candidates such as SAR405838, RO8994, CFI-400945 and their bioisosteres have been identified. Interestingly, these drug candidates act by targeting different biological sites (MDM2, PLK4, etc). As privileged structural scaffolds in searching novel ligands and drugs, spirooxindoles would deserve extra attention. Besides, the efficient asymmetric construction of structurally novel spirooxindoles is highly appreciated as the stereochemistry as represented in drug candidates discussed in this review is crucial to Fig. (9) . The identification of drug candidate RG7388 and further optimizations. the activity. Therefore, additional attention should be paid to this issue when designing spirooxindole-based derivatives for biological testing. Finally, natural products and biologically validated natural product-derived fragments are still important as a source of novel structures in designing new drugs and ligands.
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